NIH R01 · 2024
PROJECT ABSTRACT Epigenetics impacts all areas of cellular physiology, and epigenetic dysregulation is pervasive in human disease. Given the inherent reversibility of epigenetic changes, this presents a great opportunity for the discovery of novel therapeutics given the recent rapid development of epigenome-modifying drugs. Intriguingly, large-scale human sequencing efforts have revealed that sun-damaged, but clinically otherwise normal human skin, can harbor frequent mutations in epigenetic chromatin modifying enzymes. These include mutations that have been typically observed in cutaneous squamous cell carcinoma (cSCC), the second most common of all human malignancies, and a major economic…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.